上腹痛综合征患者应用黛力新疗效观察  

作　　者：李坚[1] 李璟寰[2] 

机构地区：[1]北京大学深圳医院消化内科,518036 [2]上海复旦大学附属中山医院肿瘤内科

出　　处：《中国现代药物应用》2013年第3期12-13,共2页Chinese Journal of Modern Drug Application

摘　　要：目的观察上腹痛综合征(EPS)患者在对症治疗3月以上效果不佳的同时加用氟哌噻吨美利曲辛(商品名:黛力新)10.5mg Bid po治疗的疗效。方法采用病例自身前后对照的方法A组:上腹痛综合征患者在对症治疗3月以上,平均(5.2±2.4)月,效果不佳117例患者;B组:上腹痛综合征患者在对症治疗3月以上,平均(5.2±2.4)月,效果不佳117例患者的同时加用氟哌噻吨美利曲辛10.5mg Bid po治疗2月(或症状消失2周以上停药)的两组疗效观察。结果 B组患者中11例脱离治疗、1例患者服药后因头部不适不愿意继续服药。105例患者完成治疗,起效从3～29d,平均(12±8.1)d,8例患者2月疗程结束无效,样本治疗有效率92.4%,总体治疗有效率的95%可信度区间为87.3～97.5%。结论对症治疗效果不佳的上腹痛综合征患者同时加用氟哌噻吨美利曲辛治疗(10.5mg Bid po)有较好的临床疗效、副作用少,可缩短治疗周期,有良好的社会效益和经济效益,在临床上有一定的推广价值。Objective To evaluate the effectiveness of flupentixol-melitracen in patients with Epigastric pain syndrome （EPS） who do not response well to the symptomatic treatment involving omeprazole, trimebutine Maleate, rebamipide, mosapride, bifidobacterium for more than 3 months. Methods A self-control study was conducted in which 117 patients was involved who were being in line with our inclusion criteria. And compari- son was made about the relief of symptoms before and after the treatment of flupentixol-melitracen. Results Within all the 105 patients who finished the treatment lasting 2 months, 92. 4 percentage of subject responded well to flupentixol-melitracen therapy, which indicates a 87.3-97.5% of 95% confidence interval of overall effi- ciency. While only one person quit the study because of head discomfort appearing. Conclusion With well therapeutic and economic gain, therapy combining flupentixol-melitracen could be a promising strategy for patients who are poorly responded to current treatments and suffering persistent symptoms.

关 键 词：上腹痛综合征 氟哌噻吨美利曲辛 难治性 

分 类 号：R57[医药卫生—消化系统]